RNS Number : 4102E
hVIVO PLC
10 April 2025
hVIVO plc
("hVIVO", the "Company" or the "Group")
Option Exercise, Director/PDMR Shareholding, and Total Voting Rights
hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, was notified that 202,092 options were exercised by a number of existing hVIVO employees, including Chief Financial Officer, Stephen Pinkerton, under the terms of the Company's 2020 Long Term Incentive Plan ("LTIP") at £0.02 per ordinary share.
Following this transaction, Mr Pinkerton's holding in the Company is as detailed below:
PDMR
Number of options exercised
Number of options held post exercise
Number of Ordinary Shares held
Resulting interest in fully diluted share capital %
Stephen Pinkerton
67,364
2,433,824
67,364
0.01%
Application will be made for 202,092 new Ordinary Shares to be admitted to trading on AIM. Admission is expected to become effective on 16 April 2025. Following Admission, the Company will have 687,014,088 Ordinary Shares in issue. All Ordinary Shares shall have equal voting rights and none of the Ordinary Shares are held in treasury. The total number of voting rights in the Company immediately following Admission will therefore be 687,014,088.
For further information please contact:
hVIVO plc
+44 (0)20 7756 1300
Yamin'Mo' Khan, Chief Executive Officer Stephen Pinkerton, Chief Financial Officer
Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)
+44 (0)20 7220 0500
Geoff Nash, Camilla Hume, Harriet Ward Nigel Birks - Life Science Specialist Sales Louise Talbot - Sales
Peel Hunt LLP (Joint Broker)
+44 (0)20 7418 8900
James Steel, Dr Christopher Golden
Davy (Joint Broker)
+353 (0) 1 679 6363
Anthony Farrell, Niall Gilchrist
Walbrook PR (Financial PR & IR) Paul McManus / Phillip Marriage / Louis Ashe-Jepson
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation ("MAR") EU no.596/2014. Upon the publication of this announcement via Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.
Notes to Editors
hVIVO plc (Ticker: HVO) is full-service Contract Research Organisation (CRO) and the global leader in human challenge trials. The company delivers end-to-end clinical development services to a diverse and expanding client base, including seven of the world's ten largest biopharma companies.
hVIVO specialises in conducting human challenge trials across multiple infectious and respiratory indications, leveraging its state-of-the-art quarantine facility in London-the largest of its kind worldwide. The company also offers comprehensive virology and immunology laboratory services under the hLAB brand.
Through its German subsidiary, CRS, hVIVO operates a 120-bed capacity across Mannheim and Kiel, providing early-phase clinical trial services, including first-in-human and proof-of-concept studies. Its second subsidiary, Venn Life Sciences, offers Early Drug Development Consulting and Biometry services to the biopharma sector.
The Group provides fully integrated drug development solutions from preclinical stages through Phase II trials, alongside patient recruitment via FluCamp. Additionally, its five clinical sites support outpatient Phase II and III trials, ensuring a seamless and efficient pathway from discovery to late-stage development.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:
1
Details of the person discharging managerial responsibilities/person closely associated
a.
Name of PDMR
Stephen Pinkerton
2
Reason for notification
a.
Position/Status
Chief Financial Officer
b.
Initial notification/ Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.
Name
hVIVO plc
b.
LEI
213800VT5KBM7JLIV118
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.
Description of the financial instrument, type of instrument
Identification Code
Ordinary shares of £0.001 each ISIN GB00B9275X97
b.
Nature of the transaction
Exercise of Options held under the Company'sLong Term Incentive Plan ("LTIP") and sale of resulting shares
c.
Price(s) and volume(s)
No. of Shares
Price
Option exercise
67,364
£0.02
d.
Aggregated information - Aggregated Volume - Price
See above
e.
Date of the transaction
10 April 2025
f.
Place of the transaction
Outside a trading venue
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
IOEEAELNEFDSEAA
